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Supplementary Figure S1: 68GaTate PET imaging of tumour moels in vivo. 
Tumour bearing mice were imaged on a small animal PET scanner at 1 hr post injec-
tion with 68GaTate. Representative maximum intensity projection images are shown 
for each tumour model. T, tumour; K, kidney; B, bladder.
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